The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1
Open accessAbstract
The incidence of many cancer types is significantly reduced in individuals with Down’s syndrome, and it is thought that this broad cancer protection is conferred by the increased expression of one or more of the 231 supernumerary genes on the extra copy of chromosome 21. One such gene is Down’s syndrome candidate region-1 (DSCR1, also known as RCAN1), which encodes a protein that suppresses vascular endothelial growth factor (VEGF)-mediated angiogenic signalling by the calcineurin pathway. Here we show that DSCR1 is increased in Down’s syndrome tissues and in a mouse model of Down’s syndrome. Furthermore, we show that the modest increase in expression afforded by a single extra transgenic copy of Dscr1 is sufficient to confer significant suppression of tumour growth in mice, and that such resistance is a consequence of a deficit in tumour angiogenesis arising from suppression of the calcineurin pathway. We also provide evidence that attenuation of calcineurin activity by DSCR1, together with another chromosome 21 gene Dyrk1a, may be sufficient to markedly diminish angiogenesis. These data provide a mechanism for the reduced cancer incidence in Down’s syndrome and identify the calcineurin signalling pathway, and its regulators DSCR1 and DYRK1A, as potential therapeutic targets in cancers arising in all individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116
Christakis, D., Richards, J. A., Zimmerman, F. J., Garrison, M. M., Xu, D., & Yapanel, U. H. (2009) · Cited by 2,289
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Self-citationVessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195
A mouse model for Down syndrome exhibits learning and behaviour deficits
Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913
Risks of leukaemia and solid tumours in individuals with Down's syndrome
Hasle, H., Clemmensen, I. H., & Mikkelsen, M. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05264-2 · Cited by 892
Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study
Yang, Q., Rasmussen, S. A., & Friedman, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08092-3 · Cited by 847
NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21
Arron, J. R., Winslow, M. M., Polleri, A., Chang, C.-P., Wu, H., Gao, X., Neilson, J. R., Chen, L., Heit, J. J., Kim, S. K., et al. (2006) · Nature · doi:10.1038/nature04678 · Cited by 698
Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy
Black, W. C., & Welch, H. G. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304293281706 · Cited by 547
Melero-Martin, J. M., De Obaldia, M. E., Kang, S.-Y., Khan, Z. A., Yuan, L., Oettgen, P., & Bischoff, J. (2008) · Circulation Research · doi:10.1161/circresaha.108.178590 · Cited by 488
Cited by
Claesson‐Welsh, L., & Welsh, M. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12019 · Cited by 868
Causes and consequences of aneuploidy in cancer
Gordon, D. J., Resio, B., & Pellman, D. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3123 · Cited by 815
NFAT, immunity and cancer: a transcription factor comes of age
Müller, M. R., & Rao, A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2818 · Cited by 597
Short- and long-term effects of chromosome mis-segregation and aneuploidy
Santaguida, S., & Amon, A. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4025 · Cited by 549
NFAT proteins: emerging roles in cancer progression
Mancini, M., & Toker, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2735 · Cited by 371
Interaction of calcineurin with substrates and targeting proteins
Li, H., Rao, A., & Hogan, P. G. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.09.011 · Cited by 371
DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly
Litovchick, L., Florens, L. A., Swanson, S. K., Washburn, M. P., & DeCaprio, J. A. (2011) · Genes & Development · doi:10.1101/gad.2034211 · Cited by 302
Opposing roles for calcineurin and ATF3 in squamous skin cancer
Wu, X., Nguyen, B.-C., Dziunycz, P., Chang, S., Brooks, Y., Lefort, K., Hofbauer, G. F. L., & Dotto, G. P. (2010) · Nature · doi:10.1038/nature08996 · Cited by 292
Holland, A. J., & Cleveland, D. W. (2012) · EMBO reports · doi:10.1038/embor.2012.55 · Cited by 288
The aneuploidy paradox: costs and benefits of an incorrect karyotype
Sheltzer, J. M., & Amon, A. (2011) · Trends in Genetics · doi:10.1016/j.tig.2011.07.003 · Cited by 277
Neurological phenotypes for Down syndrome across the life span
Lott, I. T. (2012) · Progress in Brain Research · doi:10.1016/b978-0-444-54299-1.00006-6 · Cited by 225
“However, other studies of subclinical hypothyroidism in the general population have failed to show significant neuropsychiatric problems (Baek et al., 2009).”
BackgroundSingle-chromosome Gains Commonly Function as Tumor Suppressors
Sheltzer, J. M., Ko, J. H., Replogle, J. M., Habibe Burgos, N. C., Chung, E. S., Meehl, C. M., Sayles, N. M., Passerini, V., Storchova, Z., & Amon, A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.004 · Cited by 201
Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy
Schadler, K. L., Thomas, N. J., Galie, P. A., Bhang, D. H., Roby, K. C., Addai, P., Till, J. E., Sturgeon, K., Zaslavsky, A., Chen, C. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11748 · Cited by 199
Self-citationPluripotent stem cells in neurodegenerative and neurodevelopmental diseases
Marchetto, M. C. N., Winner, B., & Gage, F. H. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq159 · Cited by 152
Chen, J.-Y., Lin, J.-R., Tsai, F.-C., & Meyer, T. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.09.009 · Cited by 144
Neurogenesis impairment: An early developmental defect in Down syndrome
Stagni, F., Giacomini, A., Emili, M., Guidi, S., & Bartesaghi, R. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.07.026 · Cited by 120
Minami, T., Jiang, S., Schadler, K., Suehiro, J.-I., Osawa, T., Oike, Y., Miura, M., Naito, M., Kodama, T., & Ryeom, S. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.021 · Cited by 111
Self-citationChen, Y.-L., Konieczka, J. H., Springer, D. J., Bowen, S. E., Zhang, J., Silao, F. G. S., Bungay, A. A. C., Bigol, U. G., Nicolas, M. G., Abraham, S. N., et al. (2012) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.112.002279 · Cited by 97
The Omnipresence of DYRK1A in Human Diseases
Deboever, E., Fistrovich, A., Hulme, C., & Dunckley, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169355 · Cited by 77
Rammohan, M., Harris, E., Bhansali, R. S., Zhao, E., Li, L. S., & Crispino, J. D. (2022) · Oncogene · doi:10.1038/s41388-022-02245-6 · Cited by 68
Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
Schadt, E. E., Buchanan, S., Brennand, K. J., & Merchant, K. M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00252 · Cited by 39
Synaptic Pathology of Down Syndrome
Garner, C. C., & Wetmore, D. Z. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-7091-0932-8_20 · Cited by 33
Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?
Reiche, L., Küry, P., & Göttle, P. (2019) · Cells · doi:10.3390/cells8121591 · Cited by 28
Metadata
- Authors
- Baek, K.-H., Zaslavsky, A., Lynch, R. C., Britt, C., Okada, Y., Siarey, R. J., Lensch, M. W., Park, I.-H., Yoon, S. S., Minami, T., Korenberg, J. R., Folkman, J., Daley, G. Q., Aird, W. C., Galdzicki, Z., & Ryeom, S.
- Venue
- Nature
- Published
- 2009-05-20
- Volume
- 459
- Issue
- 7250
- Pages
- 1126-1130
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2004599241
- Cited by
- 373
- References
- 29
- FWCI
- 40.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.